Richard Peters
Chairman at APREA THERAPEUTICS, INC.
Net worth: 98 164 $ as of 2024-04-29
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Paula Ragan | M | 54 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 16 years |
Shawn Iadonato | M | 54 | 16 years | |
Sijmen de Vries | M | 65 | 16 years | |
David Arkowitz | M | 62 |
Yumanity, Inc.
Yumanity, Inc. Pharmaceuticals: MajorHealth Technology Yumanity, Inc. engages in transforming drug discovery for neurodegenerative diseases services. It provides integrated discovery platforms, phenotypic screening (uHTS) platforms, in which different protein misfolding pathologies are modeled in yeast to help discover compounds to correct these pathologies; a human neuronal platform. The company was founded by Anthony N. Coles, Jr. and Susan L. Lindquist in December 2014 and is headquartered in Boston, MA. | 2 years |
Oren Gilad | M | 56 | 2 years | |
John Hamill | M | 60 | 1 years | |
Katherine Bowdish | M | 67 |
PIC Therapeutics, Inc.
PIC Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology PIC Therapeutics, Inc. operates as a biotechnology company, which focuses on transforming the treatment of cancer though the selective modulation of oncogene translation. The company was founded by Richard Peters and Gerhard Wagner and is headquartered in Boston, MA. | 4 years |
Matthew Busch | M | 50 | 20 years | |
Michael Levitan | M | 66 | - | |
Marc Duey | M | 68 | 2 years | |
Scott Dylla | M | 49 | 1 years | |
Pritesh Gandhi | M | - |
Tellbio, Inc.
Tellbio, Inc. BiotechnologyHealth Technology Tellbio, Inc. engages in biotechnology industry. The company is headquartered in West Newbury, MA. | - |
Raymond Bartoszek | M | 59 | 7 years | |
Marion Foote | F | 78 | 7 years | |
Ruud van Outersterp | M | 60 | 4 years | |
Deborah Jorn | F | 66 | 5 years | |
Michael Grissinger | M | 68 | 2 years | |
David Reese | M | 61 | 19 years | |
Mireille Sanders | F | 56 | 5 years | |
Kimberlee Drapkin | F | 56 | 1 years | |
Gabriela Gruia | M | 67 | 1 years | |
Leonard Kruimer | M | 66 | 3 years | |
Rifat Pamukcu | M | 66 | 2 years | |
John Henneman | M | 62 | 5 years | |
Bernd Seizinger | M | 67 | 9 years | |
Robert Eckert | M | 69 | 21 years | |
Brigitte Robertson | M | - |
Yumanity, Inc.
Yumanity, Inc. Pharmaceuticals: MajorHealth Technology Yumanity, Inc. engages in transforming drug discovery for neurodegenerative diseases services. It provides integrated discovery platforms, phenotypic screening (uHTS) platforms, in which different protein misfolding pathologies are modeled in yeast to help discover compounds to correct these pathologies; a human neuronal platform. The company was founded by Anthony N. Coles, Jr. and Susan L. Lindquist in December 2014 and is headquartered in Boston, MA. | - |
Jabine T. M. van der Meijs | M | 58 | 3 years | |
Stephen Toor | M | 52 | 4 years | |
Anurag Relan | M | 52 | - | |
Thierry Guillaudeux | M | 57 | 4 years | |
Paulash Mohsen | M | - |
Yumanity, Inc.
Yumanity, Inc. Pharmaceuticals: MajorHealth Technology Yumanity, Inc. engages in transforming drug discovery for neurodegenerative diseases services. It provides integrated discovery platforms, phenotypic screening (uHTS) platforms, in which different protein misfolding pathologies are modeled in yeast to help discover compounds to correct these pathologies; a human neuronal platform. The company was founded by Anthony N. Coles, Jr. and Susan L. Lindquist in December 2014 and is headquartered in Boston, MA. | - |
Gary Crocker | M | 72 |
Tellbio, Inc.
Tellbio, Inc. BiotechnologyHealth Technology Tellbio, Inc. engages in biotechnology industry. The company is headquartered in West Newbury, MA. | - |
Barbara Yanni | F | 69 | 4 years | |
Steven Baert | M | 50 | 3 years | |
Jeroen Wakkerman | M | 55 | 4 years | |
Zeev Weiss | M | 62 | 2 years | |
Jeffery Kelly | M | 63 |
Yumanity, Inc.
Yumanity, Inc. Pharmaceuticals: MajorHealth Technology Yumanity, Inc. engages in transforming drug discovery for neurodegenerative diseases services. It provides integrated discovery platforms, phenotypic screening (uHTS) platforms, in which different protein misfolding pathologies are modeled in yeast to help discover compounds to correct these pathologies; a human neuronal platform. The company was founded by Anthony N. Coles, Jr. and Susan L. Lindquist in December 2014 and is headquartered in Boston, MA. | - |
Marie N. Epstein | F | - |
Yumanity, Inc.
Yumanity, Inc. Pharmaceuticals: MajorHealth Technology Yumanity, Inc. engages in transforming drug discovery for neurodegenerative diseases services. It provides integrated discovery platforms, phenotypic screening (uHTS) platforms, in which different protein misfolding pathologies are modeled in yeast to help discover compounds to correct these pathologies; a human neuronal platform. The company was founded by Anthony N. Coles, Jr. and Susan L. Lindquist in December 2014 and is headquartered in Boston, MA. | 6 years |
Richard Heyman | M | 66 |
Yumanity, Inc.
Yumanity, Inc. Pharmaceuticals: MajorHealth Technology Yumanity, Inc. engages in transforming drug discovery for neurodegenerative diseases services. It provides integrated discovery platforms, phenotypic screening (uHTS) platforms, in which different protein misfolding pathologies are modeled in yeast to help discover compounds to correct these pathologies; a human neuronal platform. The company was founded by Anthony N. Coles, Jr. and Susan L. Lindquist in December 2014 and is headquartered in Boston, MA. | - |
Keith Baker | M | 57 | 2 years | |
Derek Miller | M | - | 21 years | |
Alan Walts | M | 64 |
PIC Therapeutics, Inc.
PIC Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology PIC Therapeutics, Inc. operates as a biotechnology company, which focuses on transforming the treatment of cancer though the selective modulation of oncogene translation. The company was founded by Richard Peters and Gerhard Wagner and is headquartered in Boston, MA. | 8 years |
N. Coles | M | 63 |
Yumanity, Inc.
Yumanity, Inc. Pharmaceuticals: MajorHealth Technology Yumanity, Inc. engages in transforming drug discovery for neurodegenerative diseases services. It provides integrated discovery platforms, phenotypic screening (uHTS) platforms, in which different protein misfolding pathologies are modeled in yeast to help discover compounds to correct these pathologies; a human neuronal platform. The company was founded by Anthony N. Coles, Jr. and Susan L. Lindquist in December 2014 and is headquartered in Boston, MA. | - |
Cecil B. Pickett | M | 78 |
Yumanity, Inc.
Yumanity, Inc. Pharmaceuticals: MajorHealth Technology Yumanity, Inc. engages in transforming drug discovery for neurodegenerative diseases services. It provides integrated discovery platforms, phenotypic screening (uHTS) platforms, in which different protein misfolding pathologies are modeled in yeast to help discover compounds to correct these pathologies; a human neuronal platform. The company was founded by Anthony N. Coles, Jr. and Susan L. Lindquist in December 2014 and is headquartered in Boston, MA. | - |
Lynne Zydowsky | M | 65 |
Yumanity, Inc.
Yumanity, Inc. Pharmaceuticals: MajorHealth Technology Yumanity, Inc. engages in transforming drug discovery for neurodegenerative diseases services. It provides integrated discovery platforms, phenotypic screening (uHTS) platforms, in which different protein misfolding pathologies are modeled in yeast to help discover compounds to correct these pathologies; a human neuronal platform. The company was founded by Anthony N. Coles, Jr. and Susan L. Lindquist in December 2014 and is headquartered in Boston, MA. | - |
Mark Pykett | M | 60 | 4 years | |
Craig Philips | M | 64 | 11 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Henri A. Termeer | M | 78 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 34 years |
Michael Kelly | M | 67 | 17 years | |
Jean Franchi | F | 57 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 19 years |
Christian Schade | M | 63 | 7 years | |
Yasir Al-Wakeel | M | 42 | 2 years | |
Christopher Viehbacher | M | 64 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | - |
David W. Beier | M | 75 | 10 years | |
Paul Eisenberg | M | - | 14 years | |
Scott Rocklage | M | 69 | 4 years | |
William A. Sullivan | M | 52 | 10 years | |
Paul Sekhri | M | 66 | 8 years | |
Sun Altbach | F | - |
PIC Therapeutics, Inc.
PIC Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology PIC Therapeutics, Inc. operates as a biotechnology company, which focuses on transforming the treatment of cancer though the selective modulation of oncogene translation. The company was founded by Richard Peters and Gerhard Wagner and is headquartered in Boston, MA. | 2 years |
Devin Smith | M | 56 | - | |
Diana McKenzie | F | 59 | 12 years | |
Gregory L. Tewalt | M | - | - | |
Michael Severino | M | 58 | 10 years | |
Josias Fantato De Pontes | M | 58 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | - |
Craig Shepherd | M | - | 7 years | |
Linda Bain | F | 53 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 3 years |
Gloria Matthews | M | - |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 6 years |
Fouad Namouni | M | 55 | 2 years | |
Peter Radovich | M | 46 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 2 years |
Brian Schiller | M | - |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 10 years |
Susan Lundeen Smuck | F | 57 | 12 years | |
Julie Feder | F | 54 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | - |
Pauline Kenny | F | 51 | 12 years | |
Daryl C. Drummond | M | - | - | |
Willard Dere | M | 70 | 11 years | |
Yamo Deniz | M | 60 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 4 years |
Leonard Schaeffer | M | 78 | 9 years | |
Gavin MacBeath | M | 54 | 24 years | |
Peter Wirth | M | 73 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 15 years |
David J. Scott | M | 71 | - | |
Michael Wyzga | M | 69 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 13 years |
Timothy Martin | M | 55 | 3 years | |
Steven J. Burakoff | M | 81 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | - |
Frank Herringer | M | 81 | 15 years | |
John Mendelsohn | M | 87 | 5 years | |
Anna Richo | F | 63 | 9 years | |
Alan Smith | M | 78 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 22 years |
Marilyn E. Wortzman | F | 77 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | 9 years |
William McClements | M | 60 | 6 years | |
Patricia Cary Sueltz | F | 71 | 2 years | |
George Demetri | M | 67 | 2 years | |
Alison Lawton | F | 62 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 25 years |
Roger W. Louis | M | 69 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 15 years |
John Smither | M | 71 | 6 years | |
Jin Long Chen | M | 61 | 4 years | |
Cynthia Flowers | F | 64 | 5 years | |
Michael Porter | M | 76 | 8 years | |
William Ashton | M | 73 | 16 years | |
Michael Wyzga | M | 35 | - |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 86 | 86.00% |
Netherlands | 14 | 14.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Richard Peters
- Personal Network